Form D · Biotechnology
SwitchPoint Bio Holding, Inc.
Wilmington, DE · CIK 0002113353
Offering snapshot reported Mar 10, 2026 · SEC filing
- Reported sold
- $5.27M Offering amount: $5.27M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 9, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 10, 2026 | Initial | $5,270,000 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06c
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-576064
Source: Form D, filed Mar 10, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Samuel Myllykangas | Director, Executive |
| Jussi Paananen | Director, Executive |
| David Proctor | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
251 Little Falls Drive
Wilmington, DE, 19808
Wilmington, DE, 19808